CONCLUSIONS:
Total annual costs for topical treatments for rosacea ranged from $25 to $483 per patient. The introduction of azelaic acid 15% foam is projected to have a minimal budget impact of $0.01 PMPM for a 1,000,000-member health plan-this is drug cost only and does not take into account any differences in effectiveness or adverse events across the compounds examined here. The cost of azelaic acid foam is exactly the same as that of azelaic acid gel; therefore, any switching from azelaic acid gel formulation to the foam formulation due to patient preference or tolerance would be budget-neutral for the health plan.
• An Excel-based economic model was developed from the payer perspective with a 1-year time horizon to evaluate the budget impact of topical treatments for the inflammatory papules and pustules of mild to moderate rosacea • The topical treatments in the model included azelaic acid foam 15%, azelaic acid gel 15%, metronidazole (gel, cream, and lotion), sodium sulfacetamide/sulfur (cream, foam, and lotion), and benzoyl peroxide (foam, gel, and lotion) • Pharmacy costs in the model were based on the published wholesale acquisition cost (WAC) for each product as of November 2015 8 -A 4-tier formulary was modeled with copay amounts of $10 for tier 1, $31 for tier 2, $56 for tier 3, and $132 for tier 4 9 • A retrospective database analysis was conducted using the MarketScan Commercial Claims and Encounters and Medical Care Supplemental Databases from 1/10/2010 to 12/31/2014 to determine the number of yearly prescriptions for each product and the product utilization by formulation • The default budget impact was based on a plan population of 1,000,000 lives, of which 14,000 patients were expected to be candidates for topical treatments for the inflammatory papules and pustules of rosacea -The estimated prevalence of rosacea was 5% 10, 11 -An estimated 28% of rosacea patients were assumed to have papulopustular rosacea 12 
METHODS
• Total annual pharmacy costs for topical treatments for rosacea ranged from $25 to $483 per patient • The introduction of azelaic acid foam is projected to have a minimal pharmacy budget impact of $0.01 PMPM for a health plan with 1,000,000 members • Any switching from azelaic acid gel to azelaic acid foam due to patient preference, efficacy, or tolerance is budget-neutral for the health plan -The cost of azelaic acid foam is exactly the same as for azelaic acid gel
CONCLUSIONS
• Real-world data for azelaic acid foam were not available in claims data -Azelaic acid foam was assumed to have the same utilization as azelaic acid gel • Combination therapy was not considered in the model • The model only includes pharmacy costs -Medical costs such as adverse events and healthcare resource utilization are not included -Differences in effectiveness were not considered in the model
LIMITATIONS RESULTS
• The annual number of prescription fills per patient was 1.6 for azelaic acid gel, sodium sulfacetamide, and benzoyl peroxide each; the annual number of prescription fills for metronidazole was 1.5 13 -Azelaic acid foam was assumed to have the same number of yearly prescription fills as azelaic acid gel (1.6) • The weighted average WAC was $146.57 for metronidazole, $312.16 for sodium sulfacetamide/sulfur, and $25.71 for benzoyl peroxide ( • In the majority of topical formulations, the vehicle is the major component because it has a large impact on the delivery of the active component and therapeutic properties of the formulation, thus also affecting efficacy and clinical outcomes [4] [5] [6] -The vehicle also affects patient preference and compliance due to the importance of tolerability for sensitive rosacea skin 6 -A new vehicle for azelaic acid, twice-daily azelaic acid foam 15%, was found to be safe and efficacious in patients with papulopustular rosacea in a phase 3 randomized double-blind trial 7 • The objective of this analysis was to evaluate the annual costs of therapy and the budget impact of topical treatments for the inflammatory papules and pustules of mild to moderate rosacea, given the introduction of azelaic acid foam to the market • In the model base case, azelaic acid foam and gel were assumed to be in formulary tier 3 and the generic products were assumed to be in formulary tier 1 • The WAC for the foam and gel formulations of azelaic acid was $255.018 • Total annual pharmacy costs were lowest for benzoyl peroxide ($25), followed by metronidazole ($205), azelaic acid foam ($318), azelaic acid gel ($318), and sodium sulfacetamide/sulfur ($483) ( Key: WAC -wholesale acquisition cost.
• At the market introduction of azelaic acid foam, the market share breakdown was 23.3% azelaic acid gel, 72.6% metronidazole, 2.7% sodium sulfacetamide/sulfur and 1.4% benzoyl peroxide 13 • The assumed market uptake of azelaic acid foam was 10%, with the market share pulled proportionally from the other topical treatments ( Table 4 • With a 10% market uptake of azelaic acid foam, the estimated pharmacy costs for rosacea topical treatments to manage patients with inflammatory papules and pustules of mild to moderate rosacea for a health plan with 1,000,000 covered lives increased from $3,308,472 to $3,423,407 for a budget impact of $114,935 (Figure 2 ) -On a per member per month (PMPM) basis, the pharmacy costs increased from $0.28 PMPM to $0.29 PMPM, for a budget impact of $0.01 PMPM ( Table 5) • This reflects drug cost only and does not take into account any differences in effectiveness or adverse events across the products examined 
